Bio-Techne Corp (TECH): Price and Financial Metrics


Bio-Techne Corp (TECH): $412.75

-1.76 (-0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TECH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

TECH Stock Summary

  • Price to trailing twelve month operating cash flow for TECH is currently 64.45, higher than 92.81% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 20.13, BIO-TECHNE Corp has a higher such ratio than 89.89% of stocks in our set.
  • With a year-over-year growth in debt of -34.25%, BIO-TECHNE Corp's debt growth rate surpasses just 10.58% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to BIO-TECHNE Corp, a group of peers worth examining would be HZNP, OMCL, SPSC, RGEN, and AKAM.
  • Visit TECH's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-techne.com.

TECH Stock Price Chart Interactive Chart >

Price chart for TECH

TECH Price/Volume Stats

Current price $412.75 52-week high $423.09
Prev. close $414.51 52-week low $200.09
Day low $410.40 Volume 92,268
Day high $419.24 Avg. volume 200,471
50-day MA $386.26 Dividend yield 0.31%
200-day MA $311.05 Market Cap 16.01B

Bio-Techne Corp (TECH) Company Bio


Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.

TECH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$412.75$52.25 -87%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for BIO-TECHNE Corp. To summarize, we found that BIO-TECHNE Corp ranked in the 15th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 87.33%. As for the metrics that stood out in our discounted cash flow analysis of BIO-TECHNE Corp, consider:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Its equity weight surpasses that of 87.51% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately only 9.46% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • TECH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 50.25% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-88%
1%-88%
2%-87%
3%-87%
4%-87%
5%-87%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TECH, try BHC, IIN, LCI, PAHC, and LMNX.


TECH Latest News Stream


Event/Time News Detail
Loading, please wait...

TECH Latest Social Stream


Loading social stream, please wait...

View Full TECH Social Stream

Latest TECH News From Around the Web

Below are the latest news stories about BIO-TECHNE Corp that investors may wish to consider to help them evaluate TECH as an investment opportunity.

Is Bio-Techne Corporation (TECH) A Smart Long-Term Buy?

Alger, an investment management firm, published its “Alger Small Cap Focus Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. During the quarter, the largest portfolio sector weightings were Health Care and Information Technology. The largest sector overweight was Health Care. Class A shares of the Alger Small Cap […]

Yahoo | April 19, 2021

The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ: TXG) Affimed N.V. (NASDAQ: AFMD) Bio-Techne Corporation (NASDAQ: TECH) - announced out-licensing of antibody treatment candidate to Xencor, Inc. (NASDAQ: XNCR) BioNTech SE (NASDAQ: BNTX) - reacted to increased EU orders for its COVID-19 vaccine in the wake of the Johnson & Johnson (NYSE: JNJ) setback Globus Medical, Inc. (NYSE: GMED) Medpace Holdings, Inc. (NASDAQ: MEDP) Medtronic plc (NYSE: MDT) Merit Medical Systems, Inc. (NASDAQ: MMSI) Natus Medical Incorporated (NASDAQ: NTUS) NuVasive, Inc. (NASDAQ: NUVA) PLx Pharma Inc. (NASDAQ: PLXP) PPD, Inc. (NASDAQ: PPD) - moved on rumors of a potential buyout by Thermo F...

Yahoo | April 15, 2021

Bio-Techne Announces Launch of Professional Assay Services - Dedicated Source for RNA in situ Hybridization Assays in Spatial Gene Expression Analysis

Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in response to increased demand for its Assay Services offered at its Newark, CA laboratory. At the heart of this re-launch is a name change from Pharma Assay Services to Professional Assay Services, with an expansion of offerings to global academic and clinical institutions, building on 10 years of experience providing services to our global pharma and biotech partners. Bio-Techne's Professional Assay Services provide in situ hybridization (ISH) gene expression analysis for target discovery, biomarker validation, drug safety assessment, and assay prototype development directly from the RNAscope™ technology experts.

Yahoo | April 15, 2021

Bio-Techne: Stealth M&A Play Looking Rich Here

Bio-Techne (TECH) has been a wildly undercovered stock on this platform, not for any good reasons as the long term value creating track record of the company is quite solid. I covered the company and the stock in 2016, nearly five years ago and concluded that I was cautious on...

The Value Investor on Seeking Alpha | April 10, 2021

Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess

Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that automates traditional Western blotting. This latest addition to the Simple Western product family offers picogram-level sensitivity through chemiluminescence detection along with the ability to perform sequential immunoassays using RePlex™. Abby is accompanied by the latest version of Compass software for Simple Western that adds to its publication-ready data analysis tools extensive lane view annotation capabilities that save hours typically spent editing in other programs. In addition, ProteinSimple has announced the pending release of Stellar™ NIR and IR modules for Jess™ which will set a new industry standard for fluorescence W...

Yahoo | April 8, 2021

Read More 'TECH' Stories Here

TECH Price Returns

1-mo 10.00%
3-mo 15.82%
6-mo 53.35%
1-year 99.50%
3-year 175.09%
5-year 357.84%
YTD 30.09%
2020 45.40%
2019 52.67%
2018 12.60%
2017 27.40%
2016 15.77%

TECH Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TECH Dividend History

Continue Researching TECH

Want to see what other sources are saying about BIO-TECHNE Corp's financials and stock price? Try the links below:

BIO-TECHNE Corp (TECH) Stock Price | Nasdaq
BIO-TECHNE Corp (TECH) Stock Quote, History and News - Yahoo Finance
BIO-TECHNE Corp (TECH) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0239 seconds.